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A n important step in drug develop-ment is the assignment of an Inter-
national Nonproprietary Name (INN)
by the World Health Organization
(WHO) that provides healthcare profes-
sionals with a unique and universally
available designated name to identify
each pharmaceutical substance. Mono-
clonal antibody INNs comprise a –mab
suffix preceded by a substem indicating
the antibody type, e.g., chimeric (-xi-),
humanized (-zu-), or human (-u-). The
WHO publishes INN definitions that
specify how new monoclonal antibody
therapeutics are categorized and adapts
the definitions to new technologies.
However, rapid progress in antibody
technologies has blurred the boundaries
between existing antibody categories and
created a burgeoning array of new
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antibody formats. Thus, revising the
INN system for antibodies is akin to aim-
ing for a rapidly moving target. The
WHO recently revised INN definitions
for antibodies now to be based on amino
acid sequence identity. These new defini-
tions, however, are critically flawed as
they are ambiguous and go against deca-
des of scientific literature. A key concern
is the imposition of an arbitrary thresh-
old for identity against human germline
antibody variable region sequences. This
leads to inconsistent classification of
somatically mutated human antibodies,
humanized antibodies as well as antibod-
ies derived from semi-synthetic/synthetic
libraries and transgenic animals. Such
sequence-based classification implies
clear functional distinction between cat-
egories (e.g., immunogenicity). How-
ever, there is no scientific evidence to
support this. Dialog between the
WHO INN Expert Group and key
stakeholders is needed to develop a
new INN system for antibodies and to
avoid confusion and miscommunica-
tion between researchers and clinicians
prescribing antibodies.
A Brief History of WHO INNs as
Applied to Monoclonal
Antibodies
International non-proprietary names
(INNs) are generic and nonproprietary
names assigned to drug substances that
are unique to the active ingredient and
are designed to enable accurate commu-
nication among healthcare professionals.
In the case of small molecules, they help
to abbreviate the very long systematic
chemical names and give an indication of
the function of a compound, whereas in
the case of protein pharmaceuticals they
give an indication of the nature of the
protein. The INN system has been coor-
dinated by the World Health Organiza-
tion (WHO) since 1950 and the suffix
‘-mab’ was introduced as the stem name
to describe monoclonal antibodies in
1990. Following on from this, a system
of substems was derived to describe the
antibody origin and disease/target indica-
tion1 with the allowance of a prefix cho-
sen by the originator. The ‘origin’
substem was necessary to distinguish
between different antibody formats, for
example: mouse (-o-), chimeric (-xi-),
humanized (-zu-) or human
(-u-) and, therefore, a definition for each
category was required in order to allow
appropriate naming for new monoclonal
antibody therapeutics. The 1997 defini-
tion1 of chimeric antibody was:
‘one that contains contiguous foreign-
derived amino acids comprising the
entire variable region of both heavy and
light chains linked to heavy and light
constant regions of human origin’;
and a humanized antibody was defined
as:
‘heavy (H) and light (L) chain variable
(V) regions, consisting of the amino
acids comprising the complementarity-
determining region (CDR) segments
(and possibly frameword [sic] residues)
from foreign antibodies inserted appro-
priately among variable regions frame-
work segments of human-derived amino
acid residues, linked to H and L con-
stant regions of human origin’.
Subsequently, in 2009, the definition
of a humanized antibody was updated2 to
a more concise description without sub-
stantially changing the meaning or com-
position of a humanized antibody,
compared to the 1997 definition (the chi-
meric definition remained the same). The
definition was as follows:
‘A humanized antibody has segments of
foreign-derived amino acids interspersed
among variable domain segments of
human-derived amino acid residues
and the humanized variable heavy and
variable light domains are linked to
heavy and light constant regions of
human origin’.
Both the 1997 and 2009 definitions of
a humanized antibody allowed for the
inclusion of foreign complementarity-
determining regions (CDRs) and addi-
tional framework residues (although not
explicitly stated in the 2009 definition as
in the 1997 definition). Definitions up to
this point were largely consistent with the
scientific literature from the last 25 to
30 years, and contributed to the creation
of an implicit hierarchy of better to worse,
as one goes from human to humanized to
chimeric to mouse.
The chimeric and humanized antibody
definitions were again updated in 20113
such that:
‘A chimeric antibody is one of which
both chain types are chimeric as a result
of antibody engineering. A chimeric
chain is a chain that contains a foreign
variable domain (V-D-J-REGION)
(originating from one species other than
human, or synthetic) linked to a con-
stant region (C-REGION) of human
origin’;
‘A humanized antibody is one of which
both chain types are humanized as a
result of antibody engineering. A
humanized chain is a chain in which
the complementarity determining
regions (CDR) of the variable domains
are foreign (originating from one species
other than human, or synthetic) whereas
the remaining chain is of human origin.
By extension an antibody is described as
humanized if more recent protocoles
[sic] were used for the humanization.’
These definitions introduced the con-
cept of synthetic sequences, i.e., sequences
that are artificially created. The chimeric
definition remained clear in that non-
human variable region sequences were
fused to human constant regions. In con-
trast, the humanized definition had
changed significantly in that it only con-
sidered a sequence to be humanized if the
CDRs alone had been transferred to
human frameworks regions. This position
is qualified by the final sentence that cre-
ates ambiguity as to whether or not an
antibody that contains additional foreign
framework residues would qualify as
“humanized” since it is not clear what
“more recent protocols” means.
In the most recent (2014) update to the
WHO INN definitions,4 the grey area
between chimeric and humanized anti-
bodies is handled in a different way and
the concept of comparing sequences ‘as a
whole’ is introduced as follows:
‘A chimeric antibody is one for which
both chain types are chimeric as a result
of antibody engineering. A chimeric
chain is a chain that contains a foreign
variable domain (originating from one
2 Volume 8 Issue 1mAbs
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species other than human, or synthetic or
engineered from any species including
human) linked to a constant region of
human origin. The variable domain of
a chimeric chain has a V region amino
acid sequence which, analyzed as a
whole, is closer to non-human species
than to human’;
‘A humanized antibody is one for which
both chain types are humanized as a
result of antibody engineering. A
humanized chain is typically a chain in
which the complementarity determining
regions (CDR) of the variable domains
are foreign (originating from one species
other than human, or synthetic) whereas
the remainder of the chain is of human
origin. Humanization assessment is
based on the resulting amino acid
sequence, and not on the methodology
per se, which allows protocols other than
grafting to be used. The variable
domain of a humanized chain has a V
region amino acid sequence which, ana-
lyzed as a whole, is closer to human
than to other species’
These latest definitions for humanized
antibodies are not directly influenced by
how the antibody sequences are obtained
and therefore accommodate the many
novel ways of humanizing a non-human
antibody sequence. They also accommo-
date the fact that the distinction between
CDRs and frameworks is artificial and
man-made, primarily through interpreting
the 3D structure and regions of diversity
between antibodies. In all of the earlier
definitions, the designation of a human-
ized antibody is confused by how CDRs
are defined as there are 3 main systems for
doing so, based upon either sequence vari-
ability (the Kabat system),5 the inclusion
of structural data (the Chothia system)6
or strict adherence to the structural loca-
tion of loops between b sheets (the
IMGT system).7 This issue has been
resolved by the stipulation that sequences
be analyzed “as a whole” and categorization
is based upon the highest level of identity
such that a humanized antibody must be
more similar to human sequences than
other species. While the definition of
“humanized” still contains the conceptual
roots of CDR grafting, the introduction of
the word “typically” indicates that transfer
of residues outside CDRs to the humanized
antibody is not anticipated, but is allowed,
and the fact that only the final overall
sequence is considered resolves the issue of
defining CDRs and frameworks. Whether
these definitions resolve the issue between
chimeric and humanized antibodies
depends on how the exact definition of
“closer to human” over the whole antibody
sequence is interpreted.
General Inconsistencies within
the Current Deﬁnitions
There are several major problems with
the latest WHO INN definitions that
have led to inconsistencies and unin-
tended outcomes in naming therapeutic
antibodies. As described above, the guide-
lines provide an outline of the require-
ments for obtaining a chimeric or
humanized designation but they make it
very difficult, if not impossible, for a
researcher designing a humanized anti-
body to determine whether or not it will
be considered humanized by the WHO
when its INN is assigned. In particular
this relates to the human sequence data-
base used for analysis and how that analy-
sis is done. At an open session of the
WHO INN Expert Group in April 2015
it was clarified that the comparison to
human sequences should be done through
the International Immunogenetics
Information System (IMGT) Domain-
GapAlign tool (www.imgt.org). Domain-
GapAlign is a tool similar to BLAST8
which interrogates the IMGT database
of antibody germline variable region genes
where the alignment score is made only
against germline sequence variable region
exons, thus omitting part of CDR3 and
the J region from the analysis. As well as
being “closer to human than to other spe-
cies” it was also explained that the top
“hit” must be human and, notwithstand-
ing the results of this analysis, the identity
to human sequences must be  85%, oth-
erwise the antibody will be designated as
chimeric. Unfortunately, these critical
parameters are not included in the above
definitions and are only, as far as we are
aware, available via the American Medical
Association9 requiring the registration of a
free account.
With respect to the identity threshold,
the rationale for using a score of similarity
to the human germline sequence as a crite-
rion for defining therapeutic antibodies has
not been clearly stated. However, one
interpretation is the notion that higher
similarity may correlate with reduced
immunogenicity.10 However, there is nei-
ther a scientific basis for a defined numeri-
cal threshold above which an antibody is
guaranteed to be non-immunogenic, nor
for the implicit assumption that the overall
percentage identity is more important than
the presence or absence of particular
sequence features, which could act as T cell
epitopes. By using an arbitrary dividing
line in an ill-defined and unknown poten-
tial for immunogenicity, it appears as if the
INN definition is attempting to provide
quantitative clarity on immunogenicity
where there is, in fact, none. Immunoge-
nicity represents a complex and multi-fac-
torial problem that is affected by many
factors beyond sequence identity.11,12
Furthermore, the omission of the
sequences encoded by the J-region genes
should be considered a major flaw in the
interpretation of the new rules, since the
recombination of the V- and J-gene seg-
ments (and for the heavy chain the V-, D-
and J-gene segments) creates the sequence
that encodes the amino acids of the com-
plete variable region domain; analysis of
the variable domain sequence ‘as a whole’
should therefore include the J-region. The
J-region makes a significant contribution
to overall human germline identity for all
engineered antibodies. Indeed it is partic-
ularly important to the humanization
process where the J-region-encoded frame-
work 4 of the parental antibody, in com-
mon with the other frameworks of the
variable domain, is replaced by human
sequences.
Another unintended consequence has
arisen as a result of using the DomainGa-
pAlign tool to align the humanized variable
regions against the IMGT species database
that also includes macaque variable region
sequences among those from other species.
The macaque variable region genes have a
higher level of identity to the human genes
than the other species in the IMGT data-
base due to their relative evolutionary prox-
imity, yet occasionally their CDR
sequences can be closer to the parental spe-
cies CDR (e.g., rat or mouse) than the
human counterparts. This can give rise to
www.tandfonline.com 3mAbs
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the situation where the DomainGapAlign
tool, which includes the CDRs in the iden-
tity calculation, gives the closest match to
the humanized sequence as macaque, even
though the frameworks share more
sequence identity with the human and the
CDRs share more sequence identity with
the rodent. This point can be illustrated by
analyzing the sequences of currently
approved humanized antibodies where
there are a number of instances of which
the top “hit” is a macaque sequence, for
example the light chain variable regions of
vedolizumab, trastuzumab and tocilizumab.
The notion that a CDR-grafting process
from a rodent antibody onto human frame-
works creates a chimeric macaque sequence
is clearly misleading. This problem is fur-
ther compounded by the fact that the com-
position of the database is not constant,
and, with the addition of ever more com-
plete genomes (and thus variable regions of
other species), there is an increased likeli-
hood that the top “hit” will be non-human.
Impact of 2014 WHO INN
Deﬁnition on Human Antibodies
The current WHO review on INN
(ref. 4) provides a substem for human
antibodies (-u-) but with no supporting
definition. Thus, it is unclear if the -u-
designation would be applied to human
antibodies derived from a growing array
of technologies. Interestingly, within the
chimeric antibody definition (“engineered
from any species, including human”),
there is the possibility that human anti-
bodies engineered for improved affinity or
other properties could be considered
chimeric. The American Medical
Association9 provide some guidance (also
adopted by the INN) on the criteria for
defining antibodies derived from different
methods e.g., isolation from various dis-
play libraries,13,14,15,16 use of animals
transgenic for human antibody
genes17,18,19,20,21 and direct isolation
from humans22,23,24,25,26 where identity
to human sequences must be 85%.
However, this threshold has recently
changed from a previous version that stip-
ulated 90%. The reason for this change
is unclear; however, it may be due to the
fact that a number of approved human
antibodies did not meet the original crite-
ria but now meet the 85% identity
threshold (Table 1).
As highlighted byTable 1, and implic-
itly acknowledged by the reduction of the
identity threshold for human antibodies,
the distinction between human antibodies
and humanized antibodies is somewhat
blurred albeit with a clear trend for human
antibodies to have higher human germline
gene identities. The problem with
reducing the threshold to  85% is that
this eliminates any sequence distinction
between humanized and human antibod-
ies. Consequently, the -zu- and -u- sub-
stems have become ambiguous and
effectively redundant. In this case the anti-
body can only be categorized by the
method used to obtain it, rather than the
resultant sequence, which goes against the
purpose of the new INN definitions.
In addition to the arguments related to
immunogenicity in the previous section,
there is no scientific rationale for the arbi-
trary  85% identity to human sequence
threshold for “human” antibodies since
even antibodies derived from human
patients may fail this test due to high levels
of somatic hypermutation; for example
the PGT121 series of anti-HIV antibodies
in which variable domains were derived in
their entirety from human patients27 pro-
vide identity scores as low as 71% for the
variable heavy chains using the recom-
mended DomainGapAlign system (the
tool is even unable to appropriately align
the variable light chains) and the patient-
derived antibody 3BNC6028,29 has identi-
ties as low as 58.8% and 69.9% in VH
and VL chains, respectively. Clearly, each
of these antibodies is human by origin,
and thus they cannot be “chimeric.” How-
ever, as discussed above, the stated and
reasonable purpose of the new INN rules
Table 1. Analysis of the sequences of 14 approved ‘fully human’ antibodies using DomainGapAlign. Values in bold do not meet the  90% threshold and
also overlap with the range of values found with humanized antibodies (see Table 2)
Variable Heavy Variable Light
% Human Identity % Human Identity
Current WHO
INN Designation
Panitumumaba 89.9 95.8 Human
Adalimumabb 93.9 95.8 Human
Canakinumaba 93.9 98.9 Human
Raxibacumabb 99.0 100.0 Human
Ipilimumaba 94.9 97.9 Human
Belimumabb 86.7 97.9 Human
Denosumaba 98.0 95.8 Human
Nivolumaba 91.8 98.9 Human
Secukinumaba 92.9 100.0 Human
Ramucirumabb 99.0 85.3 Human
Ustekinumaba 87.8 98.9 Human
Ofatumumaba 97.0 100.0 Human
Golimumaba 94.9 98.9 Human
Alirocumaba 89.8 94.1 Human
Evolocumaba 93.9 95.9 Human
aAntibody isolated from transgenic mouse;
bAntibody isolated from a phage display library.
4 Volume 8 Issue 1mAbs
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is that the final outcome determines anti-
body designation rather than the engineer-
ing history. Therefore, a new and
unintended inconsistency is created.
Indeed the conflict of antibody sequence
origin versus designation may also arise
with antibodies derived from human
libraries and transgenic mice with human-
like IgG repertoires, which all evolve
under similar selection pressures: form fol-
lows function.
Impact of 2014 WHO INN
Deﬁnition on Humanized
Antibodies
For non-human antibodies that are
humanized using contiguous human vari-
able region germline framework templates
with closest identity to the foreign antibody,
meeting the  85% threshold is challeng-
ing. Indeed a vast body of experimental
evidence (for examples see refs. 30,31,
32,33,34,35 and for a review see ref. 36)
demonstrates unequivocally that, for the
majority of non-human antibodies, transfer
of a small number of framework residues is
required to reconstitute acceptable antigen
binding and functional activity in their
humanized counterparts. A further conse-
quence of the “analyzed as a whole” concept
is that it is unlikely that antibodies human-
ized using technologies in which non-con-
tiguous human antibody fragments are
used37,38,39 will be designated as human-
ized. This concept will also effectively
penalize antibodies designed using fixed
(including consensus) frameworks (e.g.,
trastuzumab30 and pertuzumab31) that are
not selected based upon similarity to the
original murine sequence. Under the new
INN definitions such antibodies will be
considered synthetic and will therefore be
designated as chimeric; however, there is no
scientific or clinical basis for making this
distinction, as in fact trastuzumab has been
shown to have a very low immunogenicity
risk profile.40
Table 2 shows an analysis of 16 cur-
rently licensed humanized antibodies based
on the newWHO INNdefinitions (as clari-
fied at the open session in April 2015) and
reveals that, if the top “hit” rule is ignored,
only 3 antibodies would be considered
humanized, whereas 9 would be given a
mixed designation (-xizu-, where one chain
is humanized and the other is chimeric) and
4 would be chimeric. If the top “hit” rule is
applied, then no antibodies would be desig-
nated humanized and a total of 9 would be
considered chimeric.
Influence of the Foreign Sequence on
Humanization Outcome
The extent to which an antibody can
be humanized and still fall within the defi-
nition of humanized is affected largely by
the degree of identity of the CDRs of the
foreign antibody to those of the closest
human germline. For example, pertuzu-
mab31 would now receive a chimeric des-
ignation since, although both chains show
greater identity to germline human vari-
able domain sequences than to mouse
germline sequences, they are below the
85% threshold. Analysis of the heavy
chain by BLAST8 (Fig. 1(a)) reveals a
poor level of conservation between the
mouse CDRs (IMGT definition) and
their equivalent residues in the closest
human germline sequence. Given that, as
a minimum, transfer of the complete
CDRs plus adjacent conserved residues
(i.e., residues 26, 39, 55 and 66; note that
IMGT numbering7 is used throughout)
is required to recapitulate antigen binding,
Table 2. Sequence analysis of 16 approved humanized antibodies based upon the current WHO INN deﬁnitions using DomainGapAlign. Values in italics
indicate criteria for humanized designation passed. Values in bold indicate criteria failed. Assumes decimals are rounded to the nearest whole number.
Variable Heavy Variable Light
% Mouse
Identity
% Human
Identity
% Mouse
Identity
% Human
Identity
New WHO
INN Designation
Pembrolizumaba 72.4 79.6 79.8 85.1 Mixed
Vedolizumaba 81.6 84.7 85.0 85.0e Humanized
Trastuzumabb 71.4 81.6 75.8 86.3e Mixed
Obinutuzumabc 77.6 84.7 90.0 87.0f Humanized
Pertuzumabb 72.4 78.8 77.9 84.2e Chimeric
Tocilizumaba 77.3 84.8 83.2 89.5e Humanized
Certolizumabb 70.6 77.6 77.9 85.3 Mixed
Natalizumaba 79.6 83.7 86.2 80.9 Chimeric
Ranibizumabb 69.4 75.8 80.0 87.4e Mixed
Bevacizumabb 71.4 76.8 81.1 88.4e Mixed
Eculizumaba 72.4 83.7 81.1 84.2e Chimeric
Efalizumabb 68.4 76.5 83.2 89.5e Mixed
Omalizumabb 69.7 78.6 77.8 86.9e Mixed
Alemtuzumaba,d 62.0 73.7 88.4 86.3f Mixed
Palivizumaba 78.8 87.9 68.5 81.9 Mixed
Daclizumaba 81.6 82.7 74.2 84.0 Chimeric
aHumanized by grafting CDRs onto single selected VH and VL region genes;
bHumanized by grafting CDRs onto consensus VH and VL region genes;
cHumanized by grafting CDRs onto a small library of VH and VL region genes.
dCompared to rat sequences rather than mouse.
etop “hit” macaque.
ftop “hit” species of origin.
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this means that a minimum of 13 residues
will already differ between the humanized
variant and the closest human germline,
i.e. 87.6% identity. This leaves only 2 fur-
ther residues that can be manipulated out-
side the IMGT CDRs without falling
below the 85% threshold, whereas a fur-
ther 9 murine residues have been retained
to maintain affinity based upon experi-
mental evidence31 since simple transfer of
CDRs (Kabat definition) yielded an anti-
body that failed to bind to antigen. Con-
trast this with palivizumab,34 which has
87.9% variable heavy chain human germ-
line identity (Fig. 1(b)), where only 5 resi-
dues differ between murine and human
IMGT CDRs (plus adjacent residues)
and there are 7 additional framework
changes. Even if palivizumab contained 9
framework changes (as in pertuzumab), it
would still fall within the WHO INN def-
inition of a humanized antibody. In this
case, it is not the framework engineering
that made the difference, but the fortunate
coincidence that the murine and human
CDRs were more similar.
This example illustrates how the
unique sequence of the initial foreign anti-
body can influence the humanization
design process and determine how the
WHO INN Expert Group interpret its
categorization. This is underlined by the
work of Abhinandan and Martin41 analyz-
ing the “degree of humanness” of mouse
sequences. This analysis revealed that
there are some mouse variable gene fami-
lies that can easily be humanized to similar
human V-gene families even to the extent
that they share sequence identity in the
CDRs and would therefore likely meet the
new criteria for humanized. However,
there are other variable regions that are so
dissimilar (our analysis indicates 8% of
variable light and 6% of variable heavy
mouse germline genes) that they could
never meet the new criteria even if no
framework residues were transplanted,
nevertheless engineering of those sequen-
ces to reduce immunogenicity still makes
sense for clinical development. Additional
analysis of the mouse and human genomic
variable gene repertoires shows that if 5
framework residues are included in the
graft (or are present as natural somatic
mutations), then the frequency of mouse
germline sequences that can never achieve
the 85% threshold increases to 64% and
35% variable light and heavy, respectively.
Influence of framework residues on
humanization outcome
As mentioned above, CDRs were
originally defined by the inherent hyper-
variability of specific locations within the
variable domain,5 an observation that con-
curred with the function of antibodies in
generating a virtually limitless antigen
binding repertoire. Subsequently, they
were recognized as a structural feature of
the antibody,6,7 essentially defining loops
in the b-sandwich structure. Unfortu-
nately, the structural definitions of the
beginning and end of the CDRs are to
some degree arbitrary, and the definition
of sequence variation depends on the size
of the database considered. Even a func-
tional definition of CDRs is problematic
since consideration of sequence differences
between germlines (for CDR1 and
CDR2), somatic mutation frequencies, or
contact residues in structures of antigen-
antibody complexes, will all result in
slightly different definitions. Importantly,
all functional definitions would change
with increased knowledge of mutation
data and the number of antibody/antigen
complex structures determined in crystal-
lography. The IMGT CDR definitions7
are based upon strict structural classifica-
tion, where the CDRs are simply regarded
as being the loops connecting b-sheets.
This narrow definition has been very use-
ful in structural engineering of antibodies
but fails to address the complexity of their
function, and thus the impossibility of
defining a clear boundary. For instance,
the hypervariable residues lying outside
the IMGT CDRs but within the Kabat
CDRs (i.e., light chain residues: 24–26,
39, 40, 66–69, heavy chain residues: 39,
40, 55, 66–74) may not routinely make
contact with the antigen (although there
are many instances where this is the
case42,43) but they often play a critical role
in determining CDR conformation, and
key residues have been identified, based
on antibody crystal structure data,
that determine CDR “canonical
structures.”6,42 Furthermore, additional
framework residues (lying outside both
CDR definitions) have also been identi-
fied that are important in maintaining
CDR conformation (either Vernier Zone
residues,44 or canonical structure resi-
dues6,42), and in many cases these residues
overlap. Therefore, the art of antibody
humanization is not just in transferring
CDR residues from a donor sequence to
an acceptor framework, but in identifying
those additional residues that are key in
supporting the correct CDR conforma-
tion for antigen engagement. Importantly,
the final humanized sequence, in terms of
the number of framework residues that are
transferred, will depend heavily upon the
sequence of the starting foreign antibody
and its similarity to the closest human
germline (as discussed above).
We and others have a large body of
experimental data showing that transfer of
IMGT CDRs plus conserved flanking
residues from a foreign antibody to a
human template is not usually sufficient
to recapitulate antigen binding and, most
frequently, results in undetectable bind-
ing. Expanding the transferred residues to
Figure 1. BLAST 8 identity analysis of (a) pertuzumab VH chain and (b) palivizumab VH chain. The
humanized sequences are compared to their closest human germline counterparts (both GenBank
accession numbers and IMGT identiﬁers are shown). Identity, indicated by dots, and sequence dif-
ferences are shown below the humanized antibody sequences. IMGT numbering and CDR deﬁni-
tions (boxed) 7 are used with sequence gaps indicated by dashes.
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include the Kabat CDR residues usually
restores some degree of binding (and in
some cases binding equivalent to the start-
ing antibody), but in most cases varying
numbers of additional framework residues
are required. Structural analysis of the for-
eign and human template sequences
reveals the critical involvement of addi-
tional residues not included in CDRs,
such as Vernier Zone or canonical struc-
ture residues, and occasionally other
framework residues. For example, a
murine antibody that contained a frame-
work 2 identical to mouse germline
sequence IGHV5–6*01 (GenBank acces-
sion no.: AC090887) was compared to
human germline sequence databases and
the human germline IGHV3–30*01
(GenBank accession no.: M83134) was
used as template for humanization (Fig. 2
(a)). Searching of the RCSB Protein Data
Bank (www.rcsb.org) identified structure
3FFD45 as representative of the mouse
framework 2, and 2ADG46 as representa-
tive of the corresponding human frame-
work sequence. Comparison of the
framework 2 structures (Fig. 2(b)) dem-
onstrated that the identity of residue 49
dramatically affected the conformation of
the C-C’ turn. Glycine 49 in 2ADG (light
grey chain inFig. 2(b)) was able to adopt
“forbidden” dihedral angles, which
resulted in the loop and associated lysine
48 (side-chain shown) being twisted
through almost 180 compared to its
location in 3FFD (dark grey chain) where
arginine 49 adopted “permitted” dihedral
angles. Although distant from the para-
tope, this displacement of the lysine 48
side-chain was predicted to affect the
interaction of the variable heavy domain
with the variable light domain and conse-
quently antigen binding. Synthesis of
humanized antibodies containing either
glycine or arginine at position 49 revealed
that the variant containing the human
amino acid glycine 49 had a 10-fold
reduction in affinity compared to the vari-
ant containing the murine amino acid
arginine 49. This example serves to rein-
force the point that transfer of CDRs is
not normally sufficient to retain antigen
binding in humanized antibodies and
varying numbers of framework residues
need to be taken into consideration based
upon factors other than direct involve-
ment in antigen binding.
Thus, the fine-tuning of antibody/anti-
gen interactions during humanization is
achieved by framework mutations, and
this situation is fundamentally similar in
technologies used for generating “fully”
human antibodies. The isolation of anti-
bodies from synthetic libraries encoding
human antibodies, almost always includes
mutations outside the CDRs, either origi-
nating from the library design or generated
in subsequent affinity maturation steps.
Furthermore, as shown in the examples
of the anti-HIV antibodies, somatic
hypermutation is part of the underlying
process for generating potent humoral
immune responses in the human immune
system as well as in transgenic mice
expressing human IgG repertoires; frame-
work mutations are a key element of
this.29 In other words, many binding prob-
lems cannot be solved by antibodies with
 85% identity to the closest human vari-
able region germline. The immune system
knows this, as does the experienced anti-
body engineer.
Conclusions
In summary, the current WHO INN
guidance4 for the definition of chimeric,
humanized and human antibodies is
flawed for the following reasons:
 The new definitions are inconsistent
with several decades of precedence in
naming antibodies in the scientific liter-
ature as well in many cases as with pre-
viously assigned INN names for
antibodies.
 The 85% sequence threshold is arbi-
trary. Moreover, there is no scientific
evidence that this particular threshold
equates with an improved therapeutic
outcome, such as reduced immunoge-
nicity. Indeed many sequences, whether
humanized (due to the need to include
foreign framework residues) or derived
from humans (as a result of somatic
mutation), fall below this threshold.
 The exclusion of the J-region from the
INN defining process is an additional
flaw as this region forms a critical part
of the antibody variable domain.
 There is no specific definition of what
constitutes a human antibody and what
differentiates it from a humanized anti-
body. Any consideration of the meth-
odology used to derive the protein
would defeat the purpose of the INN
reform to only regard the final
sequence.
 No matter what, if any, INN suffix sub-
stem system is employed, sufficient
information for antibody engineers to
apply “the tools of their trade” is
required. The current definitions lack
sufficient information that would
Figure 2. (a) BLAST 8 comparison of murine IGHV5-6*01 framework 2 with human IGHV3-30*01
framework 2. (b) Stereo view of an overlay of framework 2 from 3FFD (dark grey) with framework 2
of 2ADG (light grey). Only back-bone atoms are shown with the exception of lysine 48. The location
of glycine/arginine 49 is indicated. The structures were analysed using Swiss-PDB Viewer 47 (http://
www.expasy.org/spdbv/).
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enable a researcher to determine how an
antibody would be categorized.
 The definitions are applied retrospec-
tively and without any notice period so
antibodies designed and engineered
under the previous WHO INN defini-
tion of what “humanized” means are
now subject to the new definition. It is
critical that a re-definition of the criteria
applied should be backward consistent
with the existing nomenclature as well
as the scientific and clinical literature.
Technologies for antibody generation
are continuously developing, and the once
simple and clear distinction between chi-
meric and humanized or human has
become increasingly blurred. Antibodies
can be made from semi-synthetic and syn-
thetic libraries, from transgenic animals,
from humanization techniques as well as
by all manners of other innovative meth-
ods. Thus, in principle the attempt to dis-
regard the technology used in the
generation of the antibody and base its
INN on the final sequence makes sense.
While the WHO must be commended
for continuously adapting the INN rules
and recognizing technological progress, it
appears that the latest definitions may
have inadvertently lead to major intrinsic
inconsistencies, and thus to unintended
confusion in the field. It appears question-
able whether a classification, once meant
to delineate “self” from “almost self” to
“non-self,” is still useful at a time when
there is almost a continuum of sequences
and of technologies for generating them.
When this is contrasted to the almost
complete ignorance of the exact level of
immunogenicity that a “human-like” anti-
body will have before going into a clinical
trial, it seems almost presumptuous to
classify antibodies in a way that will
potentially be considered by prescribers,
who may lack technical knowledge, as
simply good and bad.
A new INN system for antibodies is
urgently needed to accommodate all tech-
nologies for antibody discovery as well as
the myriad of new antibody-related for-
mats. Close dialog between the WHO
INN Expert Group and key stakeholders
is highly desirable in developing a new
INN system that effectively serves the
needs of researchers as well as healthcare
professionals. A single substem encom-
passing all engineered antibodies (perhaps
-sy- for “synthetic” or -e- for engineered
to replace and broaden -zu-) would greatly
simplify the system, or perhaps the time
has come to simply call them “-mab.”
Either of these appears a better solution
than an arbitrary categorization that lacks
any scientific foundation.
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